Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.